Cimetidine
Generic name
Cimetidine
Brand name
ATC Code
A02BA01
- Dosages
- Side effects in children
- Warnings & precautions in children
- Contra-indications in children
-
Interactions - PK
- Renal impairment
- References
Pharmacokinetics in children
No information about use in children
dose recommendation of formulary compared to licensed use (on-label versus off-label)
No information is present at this moment.
Available formulations
No information is present at this moment.
Dosages
| GERD/GORD, chronic erosive oesophagitis, therapy-resistant ulcers |
|---|
|
Renal impaiment in children > 3 months
- GFR ≥30: dose adjustment not needed
- GFR 10-30: 50% of normal reversal dose, adjustment of dosing interval not necessary.
- GFR <10: general advice is not given.
Clinical consequences
With impaired renal function, the excretion of cimetidine is delayed. As a result, the level rises and the t½ increases. Also, serum creatinine rises, as tubular secretion of creatinine decreases. However, this is a reversible effect and does not mean that renal function decreases.
Clinical Effects:
Psychological and psychomotor side effects, such as confusion, sleep disturbances, agitation, drowsiness, and hallucinations, are dose-related and more common in patients with impaired renal function.
The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here
Side effects
No information is present at this moment.
The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here
Contra-indications in children
The effervescent tablets should not be used in children with phenylketonuria because they contain aspartame.
The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here
Warnings & precautions
No information available on specific warnings and precautions in children.
Interactions
The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here
DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.
| H2-receptor antagonists | ||
|---|---|---|
| A02BA03 | ||
| A02BA02 | ||
| Proton pump inhibitors | ||
|---|---|---|
| A02BC05 | ||
| A02BC01 | ||
| A02BC02 | ||
| Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) | ||
|---|---|---|
| A02BX13 | ||
| A02BX02 | ||
References
- Apotex Europe BV, SPC Cimetidine (RVG 18080/17856/17857), www.cbg-meb.nl, Geraadpleegd 01 juni 2011, http://db.cbg-meb.nl/IB-teksten/h17856.pdf
- Kneepkens CMF et al, Werkboek Kindergastro-enterologie, VU Uitgeverij, 2002, 2e druk
- NKFK Workinggroup Acute Kidney Impairment, Extrapolation of KNMP risk analysis "Impaired renal function" for adults to children, 20 Dec 2021
Changes
Therapeutic Drug Monitoring
Overdose
